The Physician Data Query Protocol File (PDQP) contains information on over 1400 active and approved cancer treatment protocols. All clinical trials directly supported by the National Cancer Institute (NCI), as well as those voluntarily submitted by other investigators, are included. Protocols with a status of "active" are open to patient entry. "Approved" protocols have been approved by the NCI or other administrative body, but have not yet begun to enter patients. Documents contain detailed information such as protocol objectives, patient entry criteria, details of the treatment regimen, dosage modification, and participating organizations.

Producer

National Cancer Institute

R.A. Bloch International Cancer Information Center

Building 82, Room 103

Bethesda, MD 20892

PDQ Service Desk:

301-496-7403

800-624-7890

Years of Coverage

Current information

Default fields for unqualified searches

CN, PR, DI, AB, TX, DM, TY

All Display/Print Fields

AN, UP, CN, ID, PR, PS, TY, PH, TM, DI, AB, TX, LO, PO

Default Display/Print Fields

AN, UP, CN, PR, PH, TM, DI, AB, LO, PO

Update Frequency

Monthly

The following alphabetical list provides the two-letter label, the relevant alias, and an example for each PDQ Protocol File database field.

=====        ============
Label        Name/Example
=====        ============
ab           Abstract [Word Indexed]
example:     neuropsychiatric.ab.

an           Accession Number [Word and Phrase Indexed]
example 1:   010652.an.
example 2:   pdqp-010542.an.

cn           Cancer Name [Word Indexed]
example:     small cell lung.cn.

di           Drug Identifiers [Word Indexed]
example:     arabinoside.di.

id           Identification Number [Phrase Indexed]
example:     clb-9362.id.

lo           Lead Organizations [Word Indexed]
example 1:   ohio.lo.
example 2:   herbert maurer.lo.

ph           Phase [Word Indexed]
example:     phase iii.ph.

po           Participating Organizations [Word Indexed]
example:     roswell park.po.

pr           Protocol Name [Word Indexed]
example:     small cell lung.pr.

ps           Protocol Status [Word Indexed]
example 1:   "930528".ps.
example 2:   "93$4".ps.

tm           Therapy Modality [Word Indexed]
example:     radiation therapy.tm.

tx           Detail of Protocol [Word Indexed]
example:     randomized study.tx.

ty           Type of Protocol [Word Indexed]
example:     clinical trial.ty.

up           Update Code [Phrase Indexed]
example:     9703.up.

Childhood Cancers
Sentence Syntax:   limit 1 to childhood cancers

Change to PDQ Protocol File from another database

Command Syntax:        ..c/pdqp
Sentence Syntax:       use pdqp

  [Active Protocol: Currently Accepting New Patients]
Accession Number
  PDQP-010652
Update Code
  9703
Cancer Name
  Adult HD
  HD, adult
  Hodgkin's disease, adult
  Hodgkin's lymphoma, adult
  Lymphoma, Hodgkin's, adult
  Lymphoma, non-Hodgkin's, adult
  NHL, adult
  Non-Hodgkin's lymphoma, adult
  Adult HD, recurrent
  Adult HD, relapsed
  Adult Hodgkin's disease, recurrent
  Adult Hodgkin's disease, relapsed
  HD, adult, recurrent
  HD, adult, relapsed
  HD, recurrent, adult
  -sample truncated-
Identification Number
  FCCC-96004
  NCI-T95-0075H
Protocol Name
  Phase I Study of Topotecan/Paclitaxel/Carboplatin with and without
  G-CSF for Advanced Solid Tumors or Lymphomas Refractory to Standard
  Therapy (Summary Last Modified 09/96).
Protocol Status
  Date Activated:  960729
  Date Temporarily Closed:  961001.
Type of Protocol
  treatment clinical trial.
Phase
  Phase I study.
Therapy Modality
  Chemotherapy
  Hematologic toxicity attenuation
  Supportive care/therapy.
Drug Identifiers
  Carboplatin
  Carboplatin/granulocyte colony-stimulating
  factor/paclitaxel/topotecan
  Carboplatin/paclitaxel/topotecan
  Granulocyte colony-stimulating factor
  Paclitaxel
  Topotecan
  Carboplatin. Carboplat. JM-8. Paraplat. Paraplatin. Paraplatine.
  Carboplatin/granulocyte colony-stimulating
  factor/paclitaxel/topotecan. CBDCA/G-CSF/TAX/TOPO.
  Carboplatin/paclitaxel/topotecan. CBDCA/TAX/TOPO.
  Granulocyte colony-stimulating factor. Colony stimulating factor,
  granulocyte. Filgrastim. G CSF. Granulocyte colony stimulating
  factor. Lenograstim. Neupogen.
  Paclitaxel. Taxol.
  Topotecan. Hycamptamine. Hycamtin. SK&F 104864. SKF 104864..
Abstract
  OBJECTIVES:
  I.  Estimate the maximum tolerated doses of
  topotecan/paclitaxel/carboplatin (TOPO/TAX/CBDCA) with and without
  granulocyte colony-stimulating factor in patients with advanced
  solid tumors or lymphomas.
  II.  Describe the toxicity of this regimen.
  III.  Determine the pharmacokinetics of TOPO/TAX/CBDCA and whether
  TAX/CBDCA will affect the pharmacokinetics of TOPO on day 1 as
  compared to TOPO administered alone on day 5.
  IV.  Describe any clinical responses observed in these patients.
  V.  Determine topoisomerase I enzyme activity, mRNA expression, and
  protein content, when feasible, in accessible tumor tissues and in
  peripheral mononuclear cells, and determine whether these parameters
  correlate with response and toxicity.
  -sample truncated-
Detail of Protocol
  WARNING:
  Many protocols are potentially hazardous, are intended only for use
  by clinical oncologists in carefully structured settings, and may
  not prove to be more effective than standard treatment.  A
  responsible investigator associated with this protocol should be
  consulted before using this protocol.  Dose and schedule
  modifications are required for patients who develop
  gastrointestinal, hematologic, neurologic, and biochemical (renal,
  hepatic, etc.) and/or other abnormalities after the administration
  of therapy.  Additionally, Federal regulations for the protection of
  human subjects require approval of clinical trials by your local
  Institutional Review Board.
  PROTOCOL OUTLINE:
  The MTD of TOPO/TAX/CBDCA is determined without G-CSF in Part I, and
  with G-CSF in Part II.
  The following acronyms are used:
    CBDCA    Carboplatin, NSC-241240
    G-CSF    Granulocyte Colony-Stimulating Factor, NSC-614629
    TAX      Paclitaxel, NSC-125973
    TOPO     Topotecan, NSC-609699
  3-Drug Combination Chemotherapy with and without Hematologic Toxicity
  Attenuation.  TOPO/TAX/CBDCA; with and without G-CSF.
  -sample truncated-
Lead Organizations
  Lead Organization:
  Fox Chase Cancer Center
  Local ID Number:
  FCCC-96004
  Chairmen:
  Corey Jay Langer
  215-728-2985, 215-728-2687.

Some material in the PDQ database is from copyrighted publications of the respective copyright claimants. Users of the database are referred to the publication data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference. The NCI represents that PDQ is formulated with a reasonable standard of care. Except for this representation, NCI makes no representations or warranties, express or implied, including any implied warranty of merchantability or fitness for a particular purpose, with respect to PDQ. The documents contained in PDQ may be retained for personal or educational use only. Information should not be edited or modified. Any resale or redistribution of all or portions of the information is not permitted.

Because use of the PDQ database for insurance reimbursement decisions is contrary to the nature of the database, which is designed as a research tool and not to reflect all possible treatment options, customers agree to not make the database available to users who wish to use it for reimbursement decision purposes.

Revised 7 July, 1998